Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Company Overview - Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies [3][16] - The company is advancing NKX019, an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate designed to treat autoimmune diseases, particularly lupus nephritis [12][15] Leadership and Expertise - George Vratsanos, M.D., a translational immunology expert, has joined Nkarta's board of directors, bringing extensive R&D leadership experience in autoimmune diseases [3][7] - Vratsanos expressed enthusiasm for supporting Nkarta's clinical work and emphasized the potential of NK cell therapy to treat autoimmune diseases without the safety concerns associated with other cell therapies [4][7] Product Development - NKX019 utilizes NK cells derived from healthy adult donors, engineered with a humanized CD19-directed CAR and a proprietary form of interleukin-15 (IL-15) to enhance cell targeting and persistence [12] - The therapy aims to provide a safe, well-tolerated, and accessible treatment option for patients suffering from autoimmune diseases [15][16]